Lates News

In early trading on Thursday, Johnson & Johnson (NYSE: JNJ), a component stock of the Dow Jones Industrial Average, fell 0.6%. Yesterday, there were reports that the company's experimental psoriasis drug showed greater potential than the treatment from AbbVie. AbbVie is currently down 0.9%.